ArticleBioanalysis2026
From anti-drug antibody incidence to clinical relevance: interpreting highly sensitive immunogenicity assays in biosimilars.
Article in Bioanalysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHighly sensitive anti-drug antibody (ADA) assays in biosimilar comparative trials can generate high apparent positivity clustered near decision thresholds without corresponding clinical impact. Using approved biosimilars of ustekinumab and denosumab, this work retrospectively examines alternate analytical strategies to improve the biological interpretability of ADA findings.
methodsClinical ADA datasets were re-analyzed using a variability-anchored minimum screening cut point (mSCP), magnitude-aware log S/N versus percent inhibition contour visualization, and subject-level classification into preexisting, treatment-boosted, and treatment-emergent categories. A subset of the data was also subjected to longitudinal change from baseline evaluation.
resultsConventional tiered analysis produced overall screening sample positivity of 48-82% across all studies and subject-level ADA incidence >80% in 10 of the 11 arms (range, 64-100%), without any corresponding impact on pharmacokinetics, safety, or efficacy. The mSCP-based approach reduced cut point-adjacent noise-consistent signals, enabling subject-level classification that is clinically more relevant. Longitudinal analysis further separated persistent from transient responses.
conclusionBiosimilar immunogenicity testing is a confirmatory exercise against an already-approved reference, not an investigative characterization. As regulatory frameworks move toward reduced reliance on comparative Phase 3 studies, identifying persistent ADA responses at Phase 1 becomes increasingly important; a fit-for-purpose, comparability-anchored analytical strategy warrants collective regulatory rethinking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.